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SMOKING has either a beneficial or harmful effect on
the  course  and  recurrence  of  ulcerative  colitis  and
Crohn’s  disease  respectively.  Transdermal  applica-
tion of nicotine had similar effects in ulcerative colitis
and therefore was considered to be an effective basic
drug which could be further developed in the search
for new compounds in the treatment of acute exacer-
bations of corticosteroid resistant ulcerative colitis. In
this communication the short-term use of nicotine in
ulcerative colitis is reviewed.
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Introduction
Epidemiology
Although ulcerative colitis (UC) and Crohn’s disease
(CD)  are  both  indicated  as  inflammatory  bowel
diseases (IBD) with similar clinical aspects, there are
contrasting  features,  like  the  adverse  effects  of
smoking on the clinical course of these diseases. In
UC  evidence  was  found  that  the  occurrence  of
relapses  was  increased  in  ex-smokers  shortly  after
cessation.1 Smoking also has some protective effects
against disorders in which the immunological system
is in inbalance, such as Parkinson’s disease,2 Alzhei-
mer’s  disease3 and  primary  sclerosing  cholangitis
(PSC)4 (Table  1).  Approximately  70%  of  patients
suffering  from  PSC  have  associated  IBD,  most  UC,
whereas coversely, 5% of UC patients have associated
PSC.  In  contrast  with  these  observations,  smoking
seems  to  have  a  harmful  effect  on  the  course  of
CD.5
The mechanism underlying the beneficial effects of
nicotine in UC is still unknown.
Pharmacology
Smoking  cigarettes  results  in  a  fast  absorption  of
nicotine and subsequent distribution over all tissues,
followed by accumulation and simultaneously started
degradation (T1/2 approx. 2h). Smoking one cigarette
yields the mean uptake of 1mg of nicotine.6 Nicotine
binds to acetylcholine receptors located both in the
central  nervous system and the peripheral nervous
system. Presynaptic stimulation results in the release
of neurotransmittors and local hormones, which in
turn  attributes  to  either  suppression or  not  of  the
immune system.7
Immunology
Nicotine  has  an  inhibitory  effect  on  eicosanoid
production. The in vitro synthesis of thromboxane
A2 by  human  leukocytes  is  decreased8 and  overall
synthesis  of  eicosanoids  by  rectal  mucosae  from
nicotine-treated  rabbits  was  dose-dependently
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Table 1. Main effects of nicotine
Effect Reference
Diseases
Parkinson’s disease ¯ 2
Alzheimer disease ¯ 3
Primary sclerosing cholangitis ¯ 4
Ulcerative colitis ¯ 1,19
Crohn’s disease › 5,25
Pharmacology/ physiology
Presynaptic transmitter release › 7
Vasoconstriction › 7
Rectal blood flow ¯ 12
Gastric secretion, motility ¯ 13
Permeability ¯ 14
Immunology
Eicosanoid synthesis ¯ 8, 9, 10
Cytokine synthesis in vivo ¯ 11, 17
in vitro ¯ 20, 21, 22
Apoptosis ¯ 24
¯ suppression; › induction.inhibited.9 Furthermore  eicosanoid  content  was
decreased  in  bronchoalveolar  lavage  fluids  from
smokers  in  comparison  with  those  obtained  from
healthy non-smokers.10
As eicosanoids are considered to be mainly second-
ary mediators of inflammation, they will only mod-
ulate  the  course  of  the  inflammation  initiated  by
other bio-active pro-inflammatory mediators, such as
the  cytokines  tumour  necrosis  factor  a (TNFa )  or
interleukin-1b (IL-1b ).  In  an  animal  model  for  sub-
acute colitis we observed this time related release of
mediators and the beneficial effect of nicotine on the
synthesis of pro-inflammatory cytokines.11
Physiological effects
Stimulation of peripheral nicotinic receptors leads to
increased catecholamines and noradrenaline,  result-
ing in vasoconstriction, tachycardia and an increased
myocardial  contraction. After  smoking  rectal  blood
flow in UC was diminished,12 whereas both gastric
acid secretion and motility are enhanced in man.13 It
also has been suggested that nicotine tightens the gut,
which consequently leads to a diminished permeabil-
ity  and  less  availability  of  mediators  of  inflamma-
tion,14 although  increased  permeability  mainly  is
found in the ileum, more or less resembling Crohn’s
disease. The diminished availability of inflammatory
mediators  therefore  could  be  the  result  of  local
changes  in  blood  flow  and  subsequent  disturbed
distribution in the gastrointestinal tract.
The immunoregulatory role of peripheral lympho-
cytes  migrating  into  inflamed  colonic  mucosa  is
evident.  Lymphocytes  do  have  nicotinic  receptors
with a high affinity for nicotine,15 which cannot be
replaced by common muscarinic or nicotinic recep-
tor antagonists.16
The Use of Nicotine in Colitis
Experimental models
Studies on the effects of smoke describe short-term
and long-term exposure to tobacco smoke, in which
formation of pro-inflammatory mediators by alveolar
macrophages has been investigated.17 Besides that a
markedly diminished formation of cytokines by peri-
toneal macrophages was found, implicating systemic
effects  of  nicotine  on  suppression  of  the  immune
system. That  is  in  agreement  with  our  findings  in
mice,  where  both  IL-1b and  TNFa synthesis  by
colonic  mucosa  were  almost  completely  inhibited
after nicotine treatment.11
Diminished  mucosal  levels  of  pro-inflammatory
cytokines not always leads to an improvement of the
(sub)acute ulcerative colitis.18 The complex cascade
of mediators formed during the initial event and the
sub-acute and chronic phases–such as cytokines, lipid
mediators,  platelet  activating  factor,  nitric  oxide,
neuropeptides  and  local  hormones  as  angiotensin,
histamine, serotonin and substance P–leads to inter-
actions and feed-back mechanisms which still have to
be evaluated.
Clinical effects of nicotine
Transdermal nicotine for active UC during 6 weeks
has been proven to be effective as additional treat-
ment regimen besides the low-dose continuation of
corticosteroids  and/or  5-amino-salicylic  acid
(5-ASA).19 Clinical  observations  following  diary
instructions revealed a significant decreased disease
activity score (DAS), including daily stool frequency,
blood loss, stool consistency, abdominal pain, fecal
urgency  and  overall  clinical  grade.  In  the  placebo
group however, also (less) significant DAS values were
found for almost all items. Histology, mainly based on
the number of neutrophils, was only significant in the
nicotine-treated group (mean 2.6 at baseline to 1.7
after 6 weeks, scale 0–4, P < 0.001). The attributive
effect of nicotine to maintenance therapy of corticos-
teroids (< 10mg daily) or mesalasine (5-ASA) could be
due to a further suppression of cytokine synthesis.
In this study 28 of 35 patients receiving nicotine
patches were treated with mesalasine, whereas the
other seven patients received glucocorticosteroids.
We have shown that daily intake of 4g mesalasine
only partly suppressed cytokine synthesis by periph-
eral lymphocytes.20 Therefore  nicotine  only can  be
considered as an additive therapy and not a replace-
ment  therapy for  corticosteroid resistant  ulcerative
colitis. Transdermal nicotine mainly inhibits in vitro
stimulated  IL-2  production  by  human  peripheral
mononuclear cells. Only small effects on synthesis of
TNFa , IFN-gamma and IL-10 were observed.20,21
In vitro effects of nicotine on cytokine
synthesis
After incubation with prednisolone cytokine synthe-
sis  by  human  peripheral  mononuclear  cells  was
completely inhibited (10–5M). At comparable doses
nicotine only diminished the IL-2 and TNFa produc-
tion by 40–50%.22 A 35% decrease of this production
was already achieved at concentrations of 5.10–9M of
nicotine, comparable with a mean intake of 10–15
cigarettes a day. Surprisingly this inhibitory effect of
nicotine  could  not  be  reversed  by  a  number  of
agonists  and  antagonists,  such  as  carbachol  (Ach-
M-receptor agonist), atropine (Ach-M-receptor antago-
nist),  hexamethonium  and  pancuronium  (nicotinic
receptor antagonists), prednisolone and dexametha-
sone (corticosteroids) or isoprenaline and salbutamol
(b -adrenoceptor agonists).16 From these observations
we  concluded  that  a  noncholinergic  receptor  is
involved  or  that  an  irreversible  antagonism  of  the
second messenger system takes place.
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The  idea  that  a  certain  differentiation  occurs  in
subpopulations of lymphocytes after migration into
the mucosal tissue, either inflamed or non-inflamed,
lead to the classification of Th1 cell related Crohn’s
disease  and  Th2  cell  related  ulcerative  colitis.  A
disbalance  in  pro-  and  anti-inflammatory  cytokines
could  subsequently  result  in  CD  or  UC.  From  this
concept the beneficial effect of nicotine in UC and on
the other hand the harmful activity after smoking in
CD could not be clarified. New concepts have been
supposed to  unravel  mechanisms  of  IBD.  Not  only
CD4+ cells, but also mast cells and macrophages are
important  donors of  triggers  in  the  cell–cell  inter-
action which takes place in the lumen. Stimulation of
CD4+  cells  by  IL-12  will  predominantly  lead  to
synthesis of IFN-gamma and IL-2 from Th1 cells, IL-4
and IL-10 from Th2 cells and TGFb from Th3 cells.23 A
main  part  of  these  stimulated  CD4+  cells  will  dis-
appear  from  the  inflamed  region  by  apoptosis.
Neutrophil  survival  was  prolonged after incubation
with nicotine.24 This could be due to a diminished
release of IL-12 from activated macrophages. There-
fore the exclusive role of IL-12 in this interplay should
be made clear before we could conclude that smoking
and  nicotine  in  IBD  is  good  or  bad,25 based  on
cytokine patterns as prominent markers for mediators
of inflammation.
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